Total Payments
$27,640
2024 Payments
$245.58
Companies
66
Transactions
363
Medicare Patients
1,075
Medicare Billing
$198,863
Payment Breakdown by Category
Consulting$14,565 (52.7%)
Food & Beverage$7,216 (26.1%)
Travel$2,940 (10.6%)
Other$2,125 (7.7%)
Education$793.63 (2.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $14,565 | 6 | 52.7% |
| Food and Beverage | $7,216 | 334 | 26.1% |
| Travel and Lodging | $2,940 | 11 | 10.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,125 | 1 | 7.7% |
| Education | $793.63 | 11 | 2.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $12,277 | 19 | $0 (2024) |
| Exelixis Inc. | $3,490 | 12 | $0 (2019) |
| Genentech USA, Inc. | $2,476 | 18 | $0 (2022) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,533 | 5 | $0 (2019) |
| Janssen Scientific Affairs, LLC | $1,056 | 3 | $0 (2022) |
| Janssen Biotech, Inc. | $623.35 | 26 | $0 (2024) |
| Amgen Inc. | $622.56 | 26 | $0 (2022) |
| Takeda Pharmaceuticals U.S.A., Inc. | $612.84 | 10 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $408.83 | 28 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $384.37 | 22 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $245.58 | 9 | Lilly USA, LLC ($74.59) |
| 2023 | $634.25 | 24 | Genmab U.S., Inc. ($104.17) |
| 2022 | $3,938 | 28 | Genentech USA, Inc. ($2,275) |
| 2021 | $986.94 | 40 | Janssen Biotech, Inc. ($216.12) |
| 2020 | $562.95 | 24 | Amgen Inc. ($149.43) |
| 2019 | $9,961 | 59 | Celgene Corporation ($7,381) |
| 2018 | $9,449 | 70 | Celgene Corporation ($4,708) |
| 2017 | $1,862 | 109 | Novartis Pharmaceuticals Corporation ($270.02) |
All Payment Transactions
363 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $17.66 | General |
| Category: Oncology | ||||||
| 10/26/2024 | Lilly USA, LLC | — | Education | In-kind items and services | $74.59 | General |
| 10/15/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $20.22 | General |
| Category: ONCOLOGY | ||||||
| 08/21/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $17.20 | General |
| Category: ONCOLOGY | ||||||
| 07/16/2024 | ARRAY BIOPHARMA INC | LORBRENA (Drug), BRAFTOVI, MEKTOVI | Food and Beverage | In-kind items and services | $19.91 | General |
| Category: ONCOLOGY | ||||||
| 05/21/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $27.64 | General |
| Category: Oncology | ||||||
| 02/20/2024 | ARRAY BIOPHARMA INC | XALKORI (Drug), LORBRENA, BRAFTOVI | Food and Beverage | In-kind items and services | $28.89 | General |
| Category: ONCOLOGY | ||||||
| 01/23/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $17.66 | General |
| Category: Hematology | ||||||
| 01/16/2024 | Incyte Corporation | PEMAZYRE (Drug), MONJUVI | Food and Beverage | Cash or cash equivalent | $21.81 | General |
| Category: Hepatology (Liver, Pancreatic, Gall Bladder) | ||||||
| 12/26/2023 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $24.01 | General |
| Category: Rare Disease | ||||||
| 12/06/2023 | ImmunoGen, Inc. | Elahere (Biological) | Food and Beverage | In-kind items and services | $13.00 | General |
| Category: Oncology | ||||||
| 12/05/2023 | CTI BioPharma Corp. | Vonjo (Drug) | Food and Beverage | In-kind items and services | $14.99 | General |
| Category: Hematology | ||||||
| 11/07/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $22.46 | General |
| 10/03/2023 | CTI BioPharma Corp. | Vonjo (Drug) | Food and Beverage | In-kind items and services | $16.87 | General |
| Category: Hematology | ||||||
| 09/30/2023 | Incyte Corporation | MONJUVI (Drug) | Food and Beverage | Cash or cash equivalent | $19.84 | General |
| Category: Oncology | ||||||
| 09/27/2023 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $19.33 | General |
| Category: Oncology | ||||||
| 08/02/2023 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | In-kind items and services | $12.92 | General |
| Category: Oncology | ||||||
| 07/18/2023 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $17.20 | General |
| Category: Oncology | ||||||
| 07/13/2023 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $104.17 | General |
| Category: Oncology | ||||||
| 07/11/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | Education | In-kind items and services | $79.99 | General |
| 07/11/2023 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $22.46 | General |
| Category: ONCOLOGY | ||||||
| 06/28/2023 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $15.91 | General |
| Category: Oncology | ||||||
| 06/21/2023 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $16.86 | General |
| Category: ONC | ||||||
| 06/13/2023 | Pharmacyclics LLC, An AbbVie Company | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $23.17 | General |
| Category: ONCOLOGY | ||||||
| 06/06/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $21.72 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 334 | 751 | $208,064 | $95,041 |
| 2022 | 4 | 313 | 434 | $93,603 | $44,126 |
| 2021 | 8 | 238 | 401 | $99,112 | $33,867 |
| 2020 | 5 | 190 | 377 | $77,181 | $25,830 |
Total Patients
1,075
Total Services
1,963
Medicare Billing
$198,863
Procedure Codes
26
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 136 | 478 | $140,334 | $64,599 | 46.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 103 | 156 | $32,538 | $14,572 | 44.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 55 | 55 | $20,169 | $9,376 | 46.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 14 | 35 | $6,685 | $3,282 | 49.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 12 | 13 | $4,810 | $1,776 | 36.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 14 | 14 | $3,528 | $1,436 | 40.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 88 | 161 | $29,463 | $15,981 | 54.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 73 | 96 | $23,520 | $13,291 | 56.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 47 | 54 | $15,466 | $5,883 | 38.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 65 | 79 | $16,763 | $5,118 | 30.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 11 | 11 | $3,883 | $1,898 | 48.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 16 | 17 | $2,108 | $1,196 | 56.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 13 | 16 | $2,400 | $758.83 | 31.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 78 | 196 | $44,152 | $14,948 | 33.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 36 | 63 | $21,049 | $7,339 | 34.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 21 | 21 | $8,691 | $2,856 | 32.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 35 | 50 | $7,639 | $2,691 | 35.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 20 | 20 | $6,220 | $2,216 | 35.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 11 | 12 | $5,445 | $1,941 | 35.6% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Facility | 2021 | 25 | 25 | $4,750 | $1,495 | 31.5% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Facility | 2021 | 12 | 14 | $1,166 | $380.90 | 32.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 63 | 204 | $36,924 | $12,430 | 33.7% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 37 | 37 | $14,365 | $4,428 | 30.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 32 | 44 | $11,253 | $3,931 | 34.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 47 | 81 | $9,538 | $3,198 | 33.5% |
About Dr. Ike Onwere, MD
Dr. Ike Onwere, MD is a Hematology & Oncology healthcare provider based in Corvallis, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/12/2005. The National Provider Identifier (NPI) number assigned to this provider is 1467454025.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ike Onwere, MD has received a total of $27,640 in payments from pharmaceutical and medical device companies, with $245.58 received in 2024. These payments were reported across 363 transactions from 66 companies. The most common payment nature is "Consulting Fee" ($14,565).
As a Medicare-enrolled provider, Onwere has provided services to 1,075 Medicare beneficiaries, totaling 1,963 services with total Medicare billing of $198,863. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Corvallis, OR
- Active Since 08/12/2005
- Last Updated 03/01/2016
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1467454025
Products in Payments
- Pomalyst (Drug) $7,358
- Revlimid (Drug) $4,764
- Cabometyx (Drug) $3,490
- VENCLEXTA (Biological) $2,337
- GILOTRIF (Drug) $1,533
- DARZALEX (Drug) $1,010
- IMBRUVICA (Drug) $363.32
- OPDIVO (Biological) $357.10
- DARZALEX (Biological) $267.17
- KEYTRUDA (Biological) $224.10
- VELCADE (Drug) $222.73
- NINLARO (Drug) $146.05
- Kyprolis (Biological) $141.72
- REBLOZYL (Biological) $135.61
- IBRANCE (Drug) $134.72
- FOUNDATIONONE (Device) $125.51
- Lenvima (Drug) $120.07
- Aranesp (Biological) $112.18
- Epkinly (Drug) $104.17
- TUKYSA (Drug) $103.15
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.